preliminary efficacy evaluation of neoadjuvant immunotherapy combined with chemotherapy in resectable non small cell lung cancer

• DOI: 10.3779/j.issn.1009-3419.2021.102.13
• Publication Date: 2021-05-24
• Authors: Xiaoyun Song; Wei Yang; Shaofa Xu; Shuku Liu; Daping Yu; Zhidong Liu; Ning Xiao; Shijie Zhou; Chongyu Su; Xuefeng Hao; Xiaoqing Cao; Yunsong Li; Jinghui Wang; Dan Zhao
• Keywords: Male; Lung Neoplasms; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Antineoplastic Agents; lung neoplasms; Middle Aged; Neoadjuvant Therapy; surgery; Carcinoma, Non-Small-Cell Lung; Humans; Drug Therapy, Combination; Female; immunotherapy; neoadjuvant therapy; Immunotherapy; Pneumonectomy; RC254-282; Retrospective Studies

Preliminary researches conformed that neoadjuvant immunotherapy combined with chemotherapy had a significant short-term effect in resectable non-small cell lung cancer (NSCLC), but there were few clinical trials about neoadjuvant chemoimmunotherapy in China. We aimed to assess retrospectively the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage Ib-IIIb NSCLC.Twenty patients who had been diagnosed as stage Ib-IIIb NSCLC and received chemoimmunotherapy as neoadjuvant treatment between November 2019 and December 2020, in Beijing Chest Hospital, Capital Medical University were recruited. These patients received neoadjuvant treatment for 21 days as a cycle and antitumour activity and safety were evaluated every two cycles.Of 20 patients received neoadjuvant chemoimmunotherapy, 17 patients underwent surgical resection. 16 patients had R0 resection (no residual tumor resection) and 1 patient had R1 resection (microscopic residual tumor resection). Radiographic objective response rate (ORR) was 85.0% (4 complete response, 13 partial response). 5.0% (1/20) of patients had stable disease, and 10.0% (2/20) of patients had progression disease. The major pathologic response (MPR) was 47.1% (8/17), and complete pathologic response (CPR) was 29.4% (5/17). 1 case developed grade IV immune-related pneumonia (IRP) and 9 (45.0%) cases had grade III hematologic toxicity.Immunotherapy combined with chemotherapy as neoadjuvant therapy has a better efficiency and tolerable adverse effects for patients with resectable NSCLC in stage Ib-IIIb.